A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration
A Randomized, Double-masked, Comparative Clinical Study Evaluating the Efficacy, Safety, and Immunogenicity of ABP 938 8 mg Versus EYLEA® HD (Aflibercept) Delivered Via Intravitreal Injection in Participants With Neovascular Age-related Macular Degeneration
The aim of this trial is to demonstrate similarity in efficacy between ABP 938 8 mg and aflibercept (US) 8 mg by evaluating the change in best corrected visual acuity (BCVA) in participants with neovascular age-related macular degeneration (nAMD)
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Fase 3
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: Amgen Call Center
- Telefonnummer: 866-572-6436
- E-mail: medinfo@amgen.com
Studiesteder
-
-
California
-
Fullerton, California, Forenede Stater, 92835-3432
- Rekruttering
- Retina Consultants of Orange County
-
Long Beach, California, Forenede Stater, 90607
- Rekruttering
- South Coast Retina Center - RCA
-
Modesto, California, Forenede Stater, 95356
- Rekruttering
- Retinal Consultants Medical Group, Inc - Modesto (RCA)
-
Pasadena, California, Forenede Stater, 91107
- Rekruttering
- California Eye Specialists Medical Group, Inc
-
Sacramento, California, Forenede Stater, 95825
- Rekruttering
- Retinal Consultants Medical Group, Inc - Sacramento - Parkcenter Drive (RCA)
-
Santa Barbara, California, Forenede Stater, 93103
- Rekruttering
- California Retina Consultants
-
-
Colorado
-
Colorado Springs, Colorado, Forenede Stater, 80909-1183
- Rekruttering
- Retina Consultants of Southern Colorado (Colorado Springs)- RCA
-
Colorado Springs, Colorado, Forenede Stater, 80909
- Rekruttering
- Retina Consultants of Southern Colorado (Pueblo)- RCA
-
Lakewood, Colorado, Forenede Stater, 80228
- Rekruttering
- Colorado Retina Associates (RCA)
-
-
Connecticut
-
Waterford, Connecticut, Forenede Stater, 06385
- Rekruttering
- Retina Group of New England
-
-
Florida
-
Miami, Florida, Forenede Stater, 33143
- Rekruttering
- Medeye Associates - Research
-
Naples, Florida, Forenede Stater, 34103-4457
- Rekruttering
- Retina Consultants of Southwest Florida - Naples
-
Pensacola, Florida, Forenede Stater, 32503
- Rekruttering
- Advanced Research, LLC
-
-
Illinois
-
Chicago, Illinois, Forenede Stater, 60452
- Rekruttering
- University Retina and Macula Associates, PC
-
Elmhurst, Illinois, Forenede Stater, 60126
- Rekruttering
- Retina Associates
-
-
Indiana
-
Carmel, Indiana, Forenede Stater, 46032
- Rekruttering
- Associated Vitreoretinal and Uveitis Consultants
-
-
Maryland
-
Baltimore, Maryland, Forenede Stater, 21209
- Rekruttering
- The Retina Care Center- Baltimore (PRISM Vision Group)
-
Hagerstown, Maryland, Forenede Stater, 21740-5846
- Rekruttering
- Mid Atlantic Retina Specialists
-
Towson, Maryland, Forenede Stater, 21204-6833
- Rekruttering
- Retina Specialists
-
-
Massachusetts
-
Boston, Massachusetts, Forenede Stater, 02114
- Rekruttering
- Ophthalmic Consultants of Boston
-
-
Minnesota
-
Edina, Minnesota, Forenede Stater, 55435
- Rekruttering
- Retina Consultants of Minnesota (RCM) - St. Louis Park
-
-
Mississippi
-
Madison, Mississippi, Forenede Stater, 39110
- Rekruttering
- Mississippi Retina Assoc
-
-
Missouri
-
St Louis, Missouri, Forenede Stater, 63128
- Rekruttering
- The Retina Institute, Research Retina Institute (RCA)
-
-
New Jersey
-
Bloomfield, New Jersey, Forenede Stater, 07003
- Rekruttering
- Envision Ocular, LLC
-
-
New Mexico
-
Albuquerque, New Mexico, Forenede Stater, 87109
- Rekruttering
- Vision Research Center Eye Associates of New Mexico
-
-
New York
-
Liverpool, New York, Forenede Stater, 13088
- Rekruttering
- Retina Vitreous Surgeons of CNY, PC
-
Oceanside, New York, Forenede Stater, 11572
- Rekruttering
- Ophthalmic Consultants of Long Island - Research
-
Scarsdale, New York, Forenede Stater, 10583-5032
- Rekruttering
- Long Island Vitreoretinal Consultants(RCA Network)
-
-
North Carolina
-
Raleigh, North Carolina, Forenede Stater, 27607-7514
- Rekruttering
- North Carolina Retina Associates
-
Wake Forest, North Carolina, Forenede Stater, 27587
- Rekruttering
- NC Retina Associates- RCA
-
-
Ohio
-
Dublin, Ohio, Forenede Stater, 43016
- Rekruttering
- Midwest Retina - Main Office
-
-
Pennsylvania
-
Kingston, Pennsylvania, Forenede Stater, 18704-4801
- Rekruttering
- Eye Care Specialists - Kingston
-
-
South Carolina
-
Beaufort, South Carolina, Forenede Stater, 29902
- Rekruttering
- Retina Consultants of South Carolina, Charleston Neuroscience institute - Blufffon (RCA)
-
Charleston, South Carolina, Forenede Stater, 29414-5896
- Rekruttering
- Charleston Neuroscience Institute
-
Columbia, South Carolina, Forenede Stater, 29169
- Rekruttering
- Palmetto Retina Center - Main (RCA)
-
Ladson, South Carolina, Forenede Stater, 29456
- Rekruttering
- Retina Consultants of South Carolina, Charleston Neuroscience Institute- Ladson (RCA)
-
Mt. Pleasant, South Carolina, Forenede Stater, 29464
- Rekruttering
- Retina Consultants of South Carolina, Charleston Neuroscience Institute- Mount Pleasant (RCA)
-
West Columbia, South Carolina, Forenede Stater, 29169
- Rekruttering
- Palmetto Retina Center, Florence (RCA)
-
-
Tennessee
-
Nashville, Tennessee, Forenede Stater, 37203
- Rekruttering
- Tennessee Retina PC
-
-
Texas
-
Arlington, Texas, Forenede Stater, 76012
- Rekruttering
- Texas Retina Associates (TRA) - Arlington
-
Austin, Texas, Forenede Stater, 78705
- Rekruttering
- Austin Retina Associates
-
Austin, Texas, Forenede Stater, 78705
- Rekruttering
- Austin Retina Associates - Ophthalmology/Retina
-
Bellaire, Texas, Forenede Stater, 77401
- Rekruttering
- Retina Consultants of Texas - Bellaire
-
Dallas, Texas, Forenede Stater, 75231
- Rekruttering
- Texas Retina Associates (TRA) - Dallas Main
-
Fort Worth, Texas, Forenede Stater, 76104
- Rekruttering
- Texas Retina Associates - Fort Worth
-
Houston, Texas, Forenede Stater, 77401
- Rekruttering
- Retina Consultants of Texas - Katy Retina Center
-
Katy, Texas, Forenede Stater, 77494
- Rekruttering
- Retina Consultants of Texas - The Woodlands
-
San Antonio, Texas, Forenede Stater, 78240
- Rekruttering
- Retinal Consultants of Texas- San Antonio
-
Schertz, Texas, Forenede Stater, 78154
- Rekruttering
- Retina Consultants of Texas - Schertz
-
Willow Park, Texas, Forenede Stater, 76087
- Rekruttering
- Strategic Clinical Research Group, LLC
-
-
Utah
-
Salt Lake City, Utah, Forenede Stater, 84107
- Rekruttering
- Retina Associates of Utah - Retina Specialist
-
-
Virginia
-
Falls Church, Virginia, Forenede Stater, 22042-2349
- Rekruttering
- Emerson Clinical Research- Virginia Retina Specialists
-
-
Washington
-
Bellevue, Washington, Forenede Stater, 98004-3779
- Rekruttering
- Vitreoretinal Associates of Washington
-
Silverdale, Washington, Forenede Stater, 98383
- Rekruttering
- Retina Center NW PLLC
-
Spokane, Washington, Forenede Stater, 99204-2509
- Rekruttering
- Spokane Eye Clinic (OCT and optical exam
-
-
-
-
-
Fukushima, Japan, 9601295
- Rekruttering
- Fukushima Medical University Hospital - Ophthalmology
-
Tokyo, Japan, 101-8309
- Rekruttering
- Nihon University Hospital - Ophthalmology
-
-
Aichi-ken
-
Nagoya, Aichi-ken, Japan, 460-0008
- Rekruttering
- SUGITA EYE HOSPITAL - Ophthalmology
-
-
Fukuoka
-
Fukuoka, Fukuoka, Japan, 812-0011
- Rekruttering
- Hayashi Eye Hospital
-
-
Hyōgo
-
Amagasaki, Hyōgo, Japan, 660-8550
- Rekruttering
- Hyogo Prefectural Amagasaki General Medical Center - Ophthalmology
-
-
Osaka
-
Tennoji-Ku, Osaka, Japan, 543-0001
- Rekruttering
- University of the Ryukyus Hospital - Ophthalmology
-
-
Tokyo
-
Meguro-ku, Tokyo, Japan, 152-8902
- Rekruttering
- Tokyo Medical Center - Ophthalmology
-
Sendai, Tokyo, Japan, 984-8560
- Rekruttering
- Tokyo Medical University Hachioji Medical Center - Ophthalmology
-
-
Yamaguchi
-
Ube, Yamaguchi, Japan, 755-8505
- Rekruttering
- Yamaguchi University Hospital
-
Ube, Yamaguchi, Japan, 7558505
- Rekruttering
- Tokushima University Hospital - Ophthalmology
-
-
-
-
-
Riga, Letland, 1002
- Rekruttering
- P.Stradina Clinical University Hospital - Ophthalmology
-
Riga, Letland, LV-1002
- Rekruttering
- Riga East University Hospital - Department of Ophthalmology, Clinical Center "Bikernieki"
-
-
Riga
-
Riga, Riga, Letland, LV-1009
- Rekruttering
- Latvian American Eye Center
-
-
-
-
Kaunas County
-
Kaunas, Kaunas County, Litauen, 50009
- Rekruttering
- Lietuvos Sveikatos Mokslu Universitetas (LSMU) - Kauno Klinikos - ophthalmology
-
-
-
-
-
Bytom, Polen, 41-902
- Rekruttering
- Caminomed Sp. z o.o.
-
-
Kuyavian-Pomeranian Voivodeship
-
Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Polen, 85-631
- Rekruttering
- OFTALMIKA Sp. z o. o.
-
-
Lesser Poland Voivodeship
-
Krakow, Lesser Poland Voivodeship, Polen, 31-411
- Rekruttering
- COMO Centrum Okulistyki Sp. z o.o.,
-
-
Lódzkie
-
Lodz, Lódzkie, Polen, 90-302
- Rekruttering
- Santa Familia PTG Lodz
-
-
Masovian Voivodeship
-
Krakow, Masovian Voivodeship, Polen, 30-363
- Rekruttering
- Szpital sw. Rozy Sp. z o.o.
-
-
Pomeranian Voivodeship
-
Warszawa, Pomeranian Voivodeship, Polen, 01-258
- Rekruttering
- Warszawski Szpital Okulistyczny
-
-
Warmian-Masurian Voivodeship
-
Olsztyn, Warmian-Masurian Voivodeship, Polen, 10-424
- Rekruttering
- Centrum Diagnostyki i Mikrochirurgii Oka-Lens Sp. z o.o.
-
-
-
-
Bratislava Region
-
Bratislava, Bratislava Region, Slovakiet, 851 07
- Rekruttering
- Univerzitna nemocnica Bratislava - Ocna klinika SZU a UNB
-
Bratislava, Bratislava Region, Slovakiet, 81108
- Rekruttering
- Univerzitna nemocnica - Nemocnica svateho Michala, a.s. - Ocna ambulancia
-
Bratislava, Bratislava Region, Slovakiet, 821 03
- Rekruttering
- CMO Bratislava
-
Bratislava, Bratislava Region, Slovakiet, 826 06
- Rekruttering
- Univerzitna nemocnica Bratislava - Klin. oftalmologie LFUK a UNB
-
Bratislava, Bratislava Region, Slovakiet, 851 07
- Rekruttering
- Oftalmologicke centrum ProCare Betliarska
-
-
Košice Region
-
Trebišov, Košice Region, Slovakiet, 075 01
- Rekruttering
- NsP Trebisov, a.s. - Ocne oddelenie
-
-
Nitra Region
-
Nitra, Nitra Region, Slovakiet, 950 01
- Rekruttering
- Fakultna Nemocnica Nitra - Ocna Klinika
-
-
Trenčín Region
-
Banska Bystrica, Trenčín Region, Slovakiet, 975 17
- Rekruttering
- FNsP F.D.R. Banska Bystrica - II. Ocna klinika SZU
-
Trenčín, Trenčín Region, Slovakiet, 911 71
- Rekruttering
- Fakultna nemocnica Trencin - Ocna klinika
-
-
Žilina Region
-
Žilina, Žilina Region, Slovakiet, 012 07
- Rekruttering
- Fakultna nemocnica s poliklinikou Zilina - Ocne oddelenie
-
-
-
-
-
Madrid, Spanien, 28041
- Rekruttering
- Hospital Universitario 12 de Octubre - Oftalmología
-
-
Barcelona
-
San Cugat Del Valles, Barcelona, Spanien, 08190
- Rekruttering
- Hospital Universitari General de Catalunya
-
-
Catalonia
-
Barcelona, Catalonia, Spanien, 8021
- Rekruttering
- Centro de Oftalmologia Barraquer (Barraquer Ophthalmology Centre)
-
-
Navarre
-
Navarra, Navarre, Spanien, 31008
- Rekruttering
- Clinica Universidad de Navarra - Oftalmología
-
-
Sevilla
-
Santiago de Compostela, Sevilla, Spanien, 15706
- Rekruttering
- Hospital Provincial De Conxo - Oftalmología
-
-
-
-
-
Prague, Tjekkiet, 100 34
- Rekruttering
- FN Kralovske Vinohrady - Oftalmologicka klinika
-
-
Hradec Králové Region
-
Náchod, Hradec Králové Region, Tjekkiet, 547 01
- Rekruttering
- Visus, spol. s r.o. - Nachod
-
-
Ostrava-město
-
Ostrava - Poruba, Ostrava-město, Tjekkiet, 708 52
- Rekruttering
- Fakultni nemocnice Ostrava - Ocni klinika
-
-
Prague
-
Prague, Prague, Tjekkiet, 150 00
- Rekruttering
- AXON clinical
-
Prague, Prague, Tjekkiet, 128 08
- Rekruttering
- Vseobecna fakultni nemocnice v Praze - Ocni klinika
-
-
Stredoceský Kraj
-
Mladá Boleslav, Stredoceský Kraj, Tjekkiet, 293 01
- Rekruttering
- Oblastni nemocnice Mlada Boleslav, a.s., nemocnice Stredoceskeho kraje - Klaudianova nemocnice
-
-
-
-
-
Budapest, Ungarn, H-1062
- Rekruttering
- Eszak-pesti Centrumkorhaz - Honvedkorhaz
-
-
Baranya Varmegye
-
Dombóvár, Baranya Varmegye, Ungarn, 7621
- Rekruttering
- Ganglion Orvosi Kozpont - Nozologen Kft - Szemeszet
-
-
Csongrad-Csanad Varmegye
-
Szeged, Csongrad-Csanad Varmegye, Ungarn, 6720
- Rekruttering
- Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpont Szemeszeti Klinika
-
-
Hajdú-Bihar
-
Debrecen, Hajdú-Bihar, Ungarn, 4032
- Rekruttering
- Debreceni Egyetem OEC - Ophthalmology
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Men or women ≥ 50 years old, capable of giving signed informed consent
- Active, treatment-naïve subfoveal CNV lesions secondary to nAMD including juxtafoveal lesions that affect the fovea as confirmed by SD-OCT and FA in the study eye (SE)
- Total area of CNV (including both classic and occult components) > 50% of the total lesion area in the SE
- The BCVA letter score ≥ 24 and ≤ 78 letters, in the SE
- Presence of intra and/or subretinal fluid affecting the central subfield of the SE as identified by SD-OCT attributable to active CNV. The central subfield is defined as a circle with a diameter of 1 mm, centered on the fovea
Exclusion Criteria:
Participants are excluded from the study if any of the following criteria apply at either screening or baseline, unless otherwise indicated per protocol:
- Total lesion size > 12 disc areas (30.5 mm2) including blood, scars, and neovascularization, in the study eye
- Scar, fibrosis, or atrophy involving the central subfield in the study eye
- Scar or fibrosis involving > 50% of the total lesion in the study eye
- Presence of retinal pigment epithelium tears or rips involving the macula in the study eye
- History of any vitreous hemorrhage ≤ 4 weeks (28 days) before randomization in the study
- Presence of other causes of CNV, including pathologic myopia (spherical equivalent ≥ 8 diopters negative or axial length ≥ 25 mm), ocular histoplasmosis syndrome, angioid streaks, choroidal rupture, or multifocal choroiditis in the study
- Uncontrolled glaucoma (defined as IOP >25 mmHg despite treatment with anti-glaucoma medication) in the study eye
- History or clinical evidence of DR, DME, idiopathic autoimmune uveitis, or any other vascular disease affecting the retina, other than nAMD in either eye
- Evidence of active extraocular or periocular infection or inflammation (including infectious blepharitis, keratitis, scleritis, or conjunctivitis) in either eye at the time of screening or randomization
- Uncontrolled blood pressure (defined as systolic >160 mmHg or diastolic >95 mmHg). Blood pressure needs to be stable for at least 12 weeks (84 days) prior to screening
- Any prior or concomitant ocular or systemic treatment (with an investigational or approved, anti VEGF or anti-VEGF/anti-angiopoietin agent) in the SE, or surgery for nAMD in the SE, except dietary supplements or vitamins
- History or evidence of any other clinically significant disorder, condition, disease or clinical laboratory abnormality that, in the opinion of the investigator or study medical monitor, if consulted, would pose a risk to participant safety or interfere with the study evaluation or results interpretation
- Other protocol-specified exclusion criteria
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Dobbelt
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: ABP 938 8 mg
Participants will receive intravitreal ABP 938 8 mg injections at Baseline, Week 4, and Week 8. Participants will then be assessed at scheduled study visits, with Dose Regimen Adjustment (DRA) decisions beginning at Week 16 based on predefined disease-activity criteria. Injections will be administered at protocol-defined intervals ranging from every 4 to 16 weeks through the end of the study. |
IVT injection |
|
Aktiv komparator: Aflibercept (US) 8 mg
Participants will receive intravitreal Aflibercept (US) 8 mg injections at Baseline, Week 4, and Week 8. Participants will then be assessed at scheduled study visits, with DRA decisions beginning at Week 16 based on predefined disease-activity criteria. Injections will be administered at protocol-defined intervals ranging from every 4 to 16 weeks through the end of the study. |
IVT injection
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Change From Baseline in BCVA as measured by Early Treatment Diabetic Retinopathy Study (ETDRS) letter score
Tidsramme: Baseline and Week 12
|
Baseline and Week 12
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Percentage of Participants With Absence of Intraretinal Fluid (IRF) and Subretinal Fluid (SRF) in the Center Subfield, as Assessed by Spectral-Domain Optical Coherence Tomography (SD-OCT)
Tidsramme: Week 16
|
Week 16
|
|
Change from Baseline in BCVA as measured by ETDRS letter score
Tidsramme: Baseline to Week 48
|
Baseline to Week 48
|
|
Percentage of Participants Who Gained at Least 15 Letters of Vision From Baseline to Week 24
Tidsramme: Baseline to Week 24
|
Baseline to Week 24
|
|
Percentage of Participants Who Gained at Least 15 Letters of Vision From Baseline to Week 48
Tidsramme: Baseline to Week 48
|
Baseline to Week 48
|
|
Change From Baseline in Choroidal Neovascularization (CNV) Area Size as Measured by Fluorescein Angiography (FA)
Tidsramme: Baseline to Week 48
|
Baseline to Week 48
|
|
Change From Baseline in Central Subfield Thickness (CST) as Measured by SD-OCT
Tidsramme: Baseline to Week 48
|
Baseline to Week 48
|
|
Percentage of Participants Who Met Protocol-Defined DRA Criteria, as Determined by Protocol-Specified Clinical and Imaging Assessments
Tidsramme: Week 16 and Week 20
|
Week 16 and Week 20
|
|
Percentage of Participants Who Met Protocol-Defined DRA Criteria, as Determined by Protocol-Specified Clinical and Imaging Assessments
Tidsramme: Week 48
|
Week 48
|
|
Number of Participants Who Experienced Ocular Treatment-Emergent Adverse Events (TEAEs)
Tidsramme: Baseline up to Week 48
|
Baseline up to Week 48
|
|
Number of Participants Who Experienced Non-Ocular TEAEs
Tidsramme: Baseline up to Week 48
|
Baseline up to Week 48
|
|
Number of Participants Who Experienced Treatment-Emergent Events of Interest (EOI)
Tidsramme: Baseline up to Week 48
|
Baseline up to Week 48
|
|
Number of Participants Who Experienced Treatment-Emergent Serious Adverse Events (TESAEs)
Tidsramme: Baseline up to Week 48
|
Baseline up to Week 48
|
|
Number of Participants Who Developed Binding Antidrug Antibodies (ADAs)
Tidsramme: Baseline up to Week 48
|
Baseline up to Week 48
|
|
Free serum concentrations of ABP 938 8 mg
Tidsramme: Week 16, week 24 and 48 (End of Study)
|
Week 16, week 24 and 48 (End of Study)
|
|
Free serum concentrations of Aflibercept (US) 8 mg
Tidsramme: Week 16, week 24, and 48 (End of Study)
|
Week 16, week 24, and 48 (End of Study)
|
|
Pharmacokinetic (PK) parameters of ABP 938 8mg derived from concentration - time profiles following the first dose in a PK substudy
Tidsramme: From Baseline (day 1, week 0) to Day 29 (pre dose week 4)
|
From Baseline (day 1, week 0) to Day 29 (pre dose week 4)
|
|
Pharmacokinetic parameters of Aflibercept (US) 8 mg derived from concentration - time profiles following the first dose in a PK substudy
Tidsramme: From Baseline (day 1, week 0) to Day 29 (pre dose week 4)
|
From Baseline (day 1, week 0) to Day 29 (pre dose week 4)
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Efterforskere
Efterforskere
- Studieleder: MD, Amgen
Publikationer og nyttige links
Hjælpsomme links
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- 20250115
- 2025-523500-72-00 (Ctis)
- 2025 (U.S. NIH-bevilling/kontrakt)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.
IPD-delingstidsramme
Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.
IPD-delingsadgangskriterier
Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.
IPD-deling Understøttende informationstype
- STUDY_PROTOCOL
- SAP
- ICF
- CSR
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .